Investors & Media

Intarcia is committed to establishing and maintaining mature, respectful relationships with our stakeholders. We have a profound sense of accountability for the timely release of information, to be responsive to reasonable requests, and to assure the authority and accuracy of the information we provide. We look forward to engaging with our investors, the trade and consumer media, and our business partners and other stakeholders.

Latest News & Announcements

September 19, 2014

Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar in Patients with Poorly Controlled Type 2 Diabetes

September 17, 2014

Intarcia Reveals New Insights at EASD Meeting Characterizing the Burden of Poor Control and Non-Adherence to Anti-Diabetic Therapies

September 11, 2014

Intarcia Announces Two Presentations at 50th EASD Meeting: Confirms Pivital Phase 3 Data Announcement for ITCA 650 in Type 2 Diabetes in 4Q

August 5, 2014

Intarcia Announces Appointment of Dr. Sunita Zalani as Vice President, Global Head of Regulatory Affairs and Quality

June 19, 2014

Chairman & CEO Kurt Graves Presents First “Key Disruptor Award” to Tom Alessi, Ph.D., for His Innovations in Chemistry and Manufacturing that Transform Medicines For Patients

June 15, 2014

Intarcia Presents Interim Phase 3 Data at ADA Showing ITCA 650, A Once Yearly GLP-1, Markedly Reduces Blood Sugar in Patients With Very Poorly Controlled Diabetes

April 1, 2014

Intarcia Secures Second Landmark Private Financing of $200 Million – Strengthens Position To Complete Phase 3, Prepare For Launch, and Build Pipeline

February 26, 2014

Intarcia Appoints Jay Smith Head of Customer Experience & Outcomes

January 13, 2014

Intarcia CEO to Present Company Progress, Interim Phase 3 Data, and Key Milestones at J.P. Morgan

December 2, 2013

Intarcia Therapeutics Appoints Nancy Thornberry to Board of Directors

September 9, 2013

Intarcia Appoints Raymond Keane Vice President, General Counsel, and Chief Legal Officer

July 26, 2013

Intarcia Therapeutics Appoints Gino Santini to its Board of Directors

June 13, 2013

Intarcia Supports American Diabetes Association Call for Independent Review of Incretin-based Therapies

March 21, 2013

Intarcia Enrolls First Patients in "Freedom" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

February 5, 2013

Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development

November 15, 2012

Intarcia Therapeutics Secures Landmark $210 Million Financing to Fund Its Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

October 03, 2012

Intarcia Announces Presentation of Analysis Used for Dose Selection for Global ITCA 650 Phase 3 Program for Type 2 Diabetes at EASD

April 02, 2012

Intarcia Announces Expanded Appointment For Kurt Graves as Chairman, President and Chief Executive Officer

March 27, 2012

Intarcia Appoints Michelle Baron, MD, FACE, Vice President and Chief Medical Officer

December 13, 2011

Intarcia and Quintiles Finalize Innovative Alliance to Advance Global Phase 3 Program for ITCA 650 in Type 2 Diabetes

 

Investor & Media Contact

James Ahlers
james.ahlers@intarcia.com
(510) 782-7800 (office)

 

Media Kit

Product Images

2.8 MB

Device

Download

2.8 MB

Device

Download

2.7 MB

Device with Hands

Download

 

 

Video

2.1 MB

Intarcia's Platform Technology

Download (.wmv)